McKesson Corp. closed 6.64% below its 52-week high of $637.51, which the company achieved on August 2nd.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

The stock's fall snapped a two-day winning streak.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson Amplify is intended to help protect critical pharmacy services and elevate the profession by strengthening the voice ...

Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

McKesson (NYSE:MCK – Get Free Report) had its price objective cut by Citigroup from $713.00 to $677.00 in a research note ...

Park Avenue Securities LLC lessened its position in McKesson Co. (NYSE:MCK – Free Report) by 2.5% during the fourth quarter, according to the company in its most recent filing with the Securities & ...

The transaction enables McKesson to focus capital deployment and prioritize investments in strategic oncology and biopharma ...

McKesson (MCK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

McKesson (MCK) closed the most recent trading day at $585.08, moving +0.57% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.16% for the day.

Citi lowered the firm’s price target on McKesson (MCK) to $677 from $713 and keeps a Buy rating on the shares as part of a 2025 outcook for the ...